Multiple myeloma (MM) is a malignant disease of the hematopoietic system characterized by uncontrolled clonal proliferation of malignant plasma cells within the bone marrow, the presence of a monoclonal protein in the serum/urine, and the occurrence of secondary end-organ damage such as osteolytic lesions, renal insufficiency, anemia, and hypercalcemia. It is the second most common hematological malignancy in high-income countries. It accounts for 1-1.8% of all cancers, with an estimated incidence in Europe of 4.5-6.0 per 100,000 annually. Despite advancements in therapy, including using proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies most patients eventually experience relapse and succumb to the disease. Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a promising treatment for relapsed/refractory multiple myeloma. This innovative approach involves genetically modifying a patient’s T cells to express a CAR that targets specific antigens on myeloma cells, leading to their destruction. Two CAR-T products, idecabtagene vicleucel and ciltacabtagene autoleucel, have shown remarkable efficacy in clinical trials, achieving deep and durable remissions in heavily pretreated patients, and have been approved by the FDA and EMA.